Management of older Hodgkin lymphoma patients.

Management of older Hodgkin lymphoma patients. Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):233-242 Authors: Evens AM, Carter J, Loh KP, David KA Abstract Hodgkin lymphoma (HL) in older patients, commonly defined as ≥60 years of age, is a disease for which survival rates have historically been significantly lower compared with younger patients. Older HL patients appear to have different disease biology compared with younger patients, including increased incidence of mixed cellularity histology, Epstein-Barr virus-related, and advanced-stage disease. For prognostication, several studies have documented the significance of comorbidities and functional status in older HL patients, as well as the importance of achieving initial complete remission. Collectively, selection of therapy for older HL patients should be based in part on functional status, including pretreatment assessment of activities of daily living (ADL), comorbidities, and other geriatric measures (eg, cognition, social support). Treatment of fit older HL patients should be given with curative intent, regardless of disease stage. However, attention should be paid to serious treatment-related toxicities, including risk of treatment-related mortality. Although inclusion of anthracycline therapy is important, bleomycin-containing regimens (eg, doxorubicin, bleomycin, vinblastine, dacarbazine) may lead to prohibitive pulmonary toxicity, and intensive therapies (eg, bleomycin, etopo...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Related Links:

CONCLUSIONS: Although pSS is associated with a higher risk of developing NHL, the risk of NHL appears to have decreased compared with that in previous studies. Our study suggests that the risk of NHL or thyroid cancer with SS is not higher than that reported in previous studies. PMID: 31969226 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Disease relapse is the most common cause of therapy failure in NHL patients undergoing RIC alloHCT. Whether increasing TBI dose from 2Gy to 4Gy in RIC-platform can provide improved disease control without increasing non-relapse mortality (NRM) is not known. Using the CIBMTR database we evaluated the outcomes of NHL patients receiving RIC alloHCT with either Flu/2Gy TBI vs. Flu/4Gy TBI.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 24 Source Type: research
We previously reported results of allogeneic hematopoietic cell transplantation (HCT) in 93 older or medically unfit patients with non-Hodgkin's lymphoma (NHL) or chronic lymphocytic lymphoma (CLL) after conditioning with fludarabine (FLU) and 2-3 Gy total body irradiation (TBI). Three-year survival ranged from 45% to 52% depending on the underlying histology and disease stage. The major complication in those studies was disease relapse (24% at 1 year).The current prospective study in 63 NHL patients tested the hypothesis that disease relapse could be reduced, and overall survival (OS) improved, by peri-transplant rituximab (RTX).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 338 Source Type: research
ConclusionCOX-2 expression showed a tendency to be a poor prognostic factor, but it failed to provide meaningful independent information. Further larger studies are needed to investigate COX-2 as a prognostic factor and potential therapeutic target.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   T-cell Lymphoma;   Cutaneous/Peripheral T-Cell Lymphoma;   Peripheral T-cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Classified;   Primary Cutaneous T-cell Lymphoma;   Cutaneous T-Cell Lymphoma, Unspecified;   Cutaneous T-cell Lymphoma;   Follicular T-Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Sézary's Disease;   Mycosis Fungoides Intervention:   Drug: Fenretinide Sponsors:   SciTech Development,&nbs...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy. Standard chemotherapy for CHL is the ABVD regimen, which contains pneumotoxic bleomycin. This can be problematic in MTX-CHL patients suffering from an autoimmune disease (AID), such as rheumatoid arthritis (RA), as they frequently have pulmonary complications. However, brentuximab vedotin (BV)-containing chemotherapy without bleomycin (A + AVD regimen) was recently reported to show favorable efficacy for CHL, and could therefore ...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL. The diagnostic uncertainty of PMBCL can result in delayed and/or inappropriate treatment, se...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
CONCLUSION: This nationwide population-based study is the first study to report a bidirectional relationship between pSS and NHL. Our findings may suggest being alert for the patients with pSS or NHL who have early signs of the other disease in the clinical care. The underlying mechanisms of the bidirectional relationship merit further investigation. PMID: 31941803 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
Lymphoplasmacytic lymphoma (LPL) with or without Waldenstr ӧm macroglobulinemia (WM) is a rare lymphoproliferative disorder (LPD) characterized by the presence of monoclonal immunoglobulin M (IgM) paraproteinemia and bone marrow (BM) infiltration by small lymphocytes with plasmacytoid or plasma cell differentiation.1 LPL/WM constitutes less than 5% of all non-Hodgkin lymphomas (NHLs) and 1-2% of hematological malignancies.2 Patients with LPL/WM may be initially asymptomatic (smoldering WM) but over the course of their disease they may present with fatigue, shortness of breath, anemia, lymphadenopathy (LAD), splenomegaly a...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
CONCLUSIONS: This review provides moderate-certainty evidence that interim PET scan results predict OS, and very low-certainty evidence that interim PET scan results predict progression-free survival in treated individuals with HL. This evidence is primarily based on unadjusted data. More studies are needed to test the adjusted prognostic ability of interim PET against established prognostic factors. PMID: 31930780 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Biology | Education | Geriatrics | Hematology | Hodgkin's Disease | Lymphoma | Prednisone | Study | Toxicology | Universities & Medical Training